Successful treatment of long-term, poststroke, upper-limb spasticity with onabotulinumtoxinA

Phys Ther. 2011 Nov;91(11):1636-41. doi: 10.2522/ptj.20100370. Epub 2011 Aug 25.

Abstract

Background and purpose: Poststroke spasticity often negatively affects functional activities and daily living and frequently is accompanied by pain, abnormal limb postures, and contractures. The purpose of this case report is to describe the long-term benefit of botulinum toxin A in a patient with poststroke spasticity.

Case description: A 35-year-old woman with poststroke upper-limb spasticity who had lost function in her left hand was treated with onabotulinumtoxinA and physical therapy. Over 25 months, the patient received a physical therapy and occupational therapy program and received onabotulinumtoxinA injections into muscles of the left hand and arm, significantly reducing tone and facilitating recovery of function. Practical assessments, the Ashworth Scale, and electrophysiology were used to measure changes over time. No functional scales or dexterity scales were used to measure changes.

Outcomes: OnabotulinumtoxinA injections were discontinued when treatment goals were attained, and no further improvements were achieved. After more than 2½ years without further onabotulinumtoxinA treatments, the patient maintained range of motion and some functional use and dexterity in her left hand.

Discussion: This case report illustrates the efficacy and long-term benefit of onabotulinumtoxinA, combined with physical therapy and occupational therapy, in the successful treatment of poststroke spasticity.

MeSH terms

  • Adult
  • Arm / physiopathology
  • Botulinum Toxins, Type A / therapeutic use*
  • Female
  • Humans
  • Muscle Spasticity / drug therapy*
  • Muscle Spasticity / etiology*
  • Muscle Spasticity / physiopathology
  • Neuromuscular Agents / therapeutic use*
  • Occupational Therapy
  • Physical Therapy Modalities
  • Recovery of Function
  • Stroke / complications*
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A